Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Current Leases (2016 - 2025)

Arrowhead Pharmaceuticals' Current Leases history spans 13 years, with the latest figure at $7.5 million for Q4 2025.

  • For Q4 2025, Current Leases rose 14.77% year-over-year to $7.5 million; the TTM value through Dec 2025 reached $7.5 million, up 14.77%, while the annual FY2025 figure was $7.3 million, 14.93% up from the prior year.
  • Current Leases reached $7.5 million in Q4 2025 per ARWR's latest filing, up from $7.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $10.6 million in Q3 2023 to a low of $1.3 million in Q1 2021.
  • Average Current Leases over 5 years is $4.6 million, with a median of $3.2 million recorded in 2022.
  • Peak YoY movement for Current Leases: skyrocketed 280.51% in 2023, then crashed 39.96% in 2024.
  • A 5-year view of Current Leases shows it stood at $2.8 million in 2021, then decreased by 5.73% to $2.7 million in 2022, then increased by 28.42% to $3.4 million in 2023, then surged by 91.76% to $6.6 million in 2024, then grew by 14.77% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Current Leases are $7.5 million (Q4 2025), $7.3 million (Q3 2025), and $7.0 million (Q2 2025).